MorphoSys AG (ETR:MOR) has been assigned a €76.00 ($87.36) target price by equities researchers at Commerzbank Ag in a research note issued to investors on Friday. The firm currently has a “buy” rating on the stock.
Several other research analysts also recently weighed in on the stock. Independent Research GmbH set a €77.00 ($88.51) target price on shares of MorphoSys AG and gave the company a “buy” rating in a research note on Monday, May 29th. Berenberg Bank set a €68.00 ($78.16) target price on shares of MorphoSys AG and gave the company a “buy” rating in a research note on Thursday, May 25th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($63.22) target price on shares of MorphoSys AG and gave the company a “neutral” rating in a research note on Tuesday, June 6th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of €67.00 ($77.01).
Shares of MorphoSys AG (ETR MOR) opened at 67.482 on Friday. The firm’s market capitalization is €1.94 billion. MorphoSys AG has a 12-month low of €35.72 and a 12-month high of €67.51. The firm’s 50-day moving average is €62.72 and its 200-day moving average is €54.66.
COPYRIGHT VIOLATION NOTICE: “MorphoSys AG (ETR:MOR) PT Set at €76.00 by Commerzbank Ag” was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://transcriptdaily.com/2017/07/18/morphosys-ag-etrmor-pt-set-at-76-00-by-commerzbank-ag.html.
MorphoSys AG Company Profile
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company’s operating segments include Proprietary Development and Partnered Discovery.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.